How to Qualify for Severe Asthma Biologics: Doctor Evaluation Protocols

When asthma remains uncontrolled despite high-dose inhaled therapies and other standard treatments, biologic medicines can be life-changing. These targeted therapies aim at specific immune pathways driving severe asthma. Below is a clear guide to how doctors evaluate and determine if you're a candidate for severe asthma biologics.

---

1. Confirm the Diagnosis of Severe Asthma

Before considering biologics, physicians must make sure your asthma is truly severe, not just poorly controlled. This involves:

• Accurate medical history
  • Duration and frequency of symptoms (daytime, nighttime, activity-limiting)
  • Number of exacerbations in the past 12 months (need for oral steroids, ER visits, or hospitalizations)
  • Current medications, dosages, and adherence

• Objective lung function testing
  • Spirometry before and after a bronchodilator (FEV₁, FEV₁/FVC)
  • Peak expiratory flow monitoring, if needed

• Assessment of comorbidities
  • Allergic rhinitis, nasal polyps, chronic sinusitis
  • Gastroesophageal reflux disease (GERD)
  • Obesity, obstructive sleep apnea, anxiety/depression

• Lifestyle and environmental review
  • Allergen and irritant exposure (dust mites, pets, smoke)
  • Smoking status or second-hand smoke
  • Occupational triggers

---

2. Optimize Standard Therapy

Biologics come into play when you've already tried and optimized conventional treatments:

• High-dose inhaled corticosteroids (ICS) plus a long-acting beta-agonist (LABA)
• Long-acting muscarinic antagonist (LAMA), when indicated
• Leukotriene receptor antagonists or theophylline, in select cases
• Short courses of oral corticosteroids for exacerbations, but not as maintenance

Doctors will check that:

• You're using inhalers correctly
• You refill medications on schedule
• You've addressed adherence barriers (cost, technique, understanding)

---

3. Exclude Other Conditions and Mimickers

Severe asthma can look like other diseases. Physicians often order:

• Chest imaging (X-ray, CT scan) to rule out bronchiectasis, interstitial lung disease
• Cardiac evaluation if cardiac asthma or heart failure is suspected
• Sputum culture or bronchoscopy, if infection or airway abnormality is possible

Ensuring you truly have "severe asthma" and not another condition avoids unnecessary biologic use.

---

4. Identify Asthma Phenotype and Biomarkers

Biologics target specific immune pathways. Your doctor will measure markers that predict response:

• Blood eosinophil count
  • Eosinophils ≥ 150 cells/μL at screening or ≥ 300 cells/μL in the past year favor anti-IL-5 therapy (e.g., mepolizumab, benralizumab).

• Total serum IgE and allergy testing
  • IgE levels between 30–700 IU/mL plus evidence of allergic sensitization (skin prick or specific IgE) suggest omalizumab.

• Fractional exhaled nitric oxide (FeNO)
  • Elevated FeNO (≥ 25 ppb) can predict response to anti-IL-4/IL-13 therapy (dupilumab) or anti-IgE.

• Other phenotypic clues
  • Chronic nasal polyps, aspirin-exacerbated respiratory disease—dupilumab may be especially effective
  • Early-onset allergic asthma vs. late-onset eosinophilic asthma

---

5. Document Exacerbation History

Severe exacerbations drive the choice to use biologics. Physicians typically look for:

• ≥ 2 exacerbations in the past 12 months requiring systemic corticosteroids
• ≥ 1 hospitalization or ER admission for asthma in the past year
• Ongoing need for oral steroids (≥ 2 courses or low-dose maintenance)

Meeting these criteria under optimized therapy flags you as a candidate for advanced treatment.

---

6. Specialist Evaluation and Shared Decision-Making

Once initial screening and tests suggest eligibility, you'll usually be referred to an asthma specialist or allergist. At this stage:

• The specialist reviews all data—history, lung function, biomarkers
• Benefits and risks of each biologic are discussed in plain language
• Real-world considerations—cost, insurance coverage, injection frequency—are weighed
• A plan for monitoring response and side effects is established

---

7. Insurance and Regulatory Criteria

In many countries, payers follow established guidelines when approving biologics. Common requirements include:

• Documentation of severe asthma as per international guidelines (GINA, ERS/ATS)
• Evidence of adherence to high-dose ICS/LABA plus additional controllers
• Laboratory proof of key biomarkers (eosinophils, IgE, FeNO)
• Records of exacerbations and steroid use over the past year

Your doctor's detailed clinical note is essential for approval.

---

8. Starting Biologic Therapy

Once approved, the typical process is:

1. Baseline assessment
   – Symptoms, lung function, exacerbation history, biomarker levels
2. Loading dose / first injection in clinic, with observation for immediate reactions
3. Regular follow-up visits every 4–12 weeks to monitor:
   • Symptom improvement
   • Lung function (spirometry)
   • Exacerbation rate
   • Biomarker changes
4. Adjustment or discontinuation if no meaningful benefit after 4–6 months

---

Commonly Prescribed Biologics for Severe Asthma

Biologic	Target	Key Eligibility Criteria
Omalizumab	IgE	Allergic asthma, IgE 30–700 IU/mL
Mepolizumab	IL-5	Blood eos ≥ 150 cells/μL
Reslizumab	IL-5	Blood eos ≥ 400 cells/μL, weight ≥ 30 kg
Benralizumab	IL-5 receptor	Blood eos ≥ 300 cells/μL
Dupilumab	IL-4/IL-13 receptor	Eos ≥ 150 cells/μL or FeNO ≥ 25 ppb

---

Tracking Your Progress

To assess if a biologic is working, your doctor will follow:

• Reduction in oral steroid use
• Fewer exacerbations
• Better lung function (improved FEV₁)
• Enhanced quality of life (sleep, exercise tolerance)

Adjustments are made based on these outcome measures.

---

When to Re-Evaluate or Switch

If after 4–6 months you haven't hit key targets, your doctor may:

• Check adherence and injection technique
• Rule out new triggers or comorbidities
• Consider switching to another biologic with a different target

---

Take the Next Step

If you suspect your asthma is severe or uncontrolled, preparing for your doctor's appointment with detailed symptom information can make a real difference in your evaluation. Taking a few minutes to complete a free symptom assessment before your appointment can help you identify patterns you might have missed and provide your healthcare team with a comprehensive overview of your respiratory symptoms—making your biologic qualification evaluation more thorough and productive.

---

Final Thoughts

Qualifying for severe asthma biologics is a stepwise process that balances objective tests, symptom history, biomarker findings, and your personal treatment goals. Biologics aren't first-line therapy—they're reserved for those who truly need specialized care after exhausting other options. If you think you might benefit:

• Keep a detailed symptom and medication diary
• Ensure you're using inhalers correctly
• Discuss your full history of asthma flares with your doctor

Always talk to a qualified healthcare professional about any breathing problems that could be life-threatening or serious. Your doctor can help you determine if you meet the criteria for biologic therapy and guide you toward the best treatment plan.